The BRAF V600E Mutation Detection by quasa Sensitive Real-Time PCR Assay in Northeast Romania Melanoma Patients
Authors:
- Elena Porumb-AndreseEPElena Porumb-Andrese
- Ramona Gabriela UrsuRamona Gabriela Ursu
- Iuliu IvanovIIIuliu Ivanov
- Irina-Draga CaruntuICIrina-Draga Caruntu
- Vlad PorumbVPVlad Porumb
- Dan FerariuDFDan Ferariu
- Costin DamianCDCostin Damian
- Delia CiobanuDCDelia Ciobanu
- Cristina TerinteCTCristina Terinte
- Luminita Smaranda IancuLILuminita Smaranda Iancu
Open Access
- 13 October 2021
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 11 (20) , 9511
Abstract
Background: The prevalence of melanoma in Romanian patients is underestimated. There is a need to identify the BRAF V600E mutation to accurately treat patients with the newest approved BRAF inhibitor therapy. This is a pilot study in which we first aimed to choose the optimal DNA purification method from formalin fixation and paraffin embedding (FFPE) malignant melanoma skin samples to assess the BRAF mutation prevalence and correlate it with clinical pathological parameters. Methods: 30 FFPE samples were purified in parallel with two DNA extraction kits, a manual and a semi-automated kit. The extracted DNA in pure and optimum quantity was tested for the BRAF V600E mutation using the quantitative allele-specific amplification (quasa) method. quasa is a method for the sensitive detection of mutations that may be present in clinical samples at low levels. Results: The BRAF V600E mutation was detected in 60% (18/30) samples in patients with primary cutaneous melanoma of the skin. BRAFV600E mutation was equally distributed by gender and was associated with age >60, nodular melanoma, and trunk localization. Conclusions: The high prevalence of BRAF V600E mutations in our study group raises awareness for improvements to the national reporting system and initiation of the target therapy for patients with malignant melanoma of the skin.Keywords
This publication has 27 references indexed in Scilit:
- DNA Methylation Characteristics of Primary Melanomas with Distinct Biological BehaviourPLOS ONE, 2014
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous MelanomasThe Journal of Molecular Diagnostics, 2013
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Melanoma epidemiology and trendsClinics in Dermatology, 2009
- Prevalence of Exon 15 BRAF Mutations in Primary Melanoma of the Superficial Spreading, Nodular, Acral, and Lentigo Maligna SubtypesJournal of Investigative Dermatology, 2005
- Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factorsEuropean Journal of Cancer, 2005
- BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organsJournal of Clinical Pathology, 2005
- Influence of Histochemical and Immunohistochemical Stains on Polymerase Chain ReactionLaboratory Investigation, 2000